Solara Active Pharma Sciences has filed a revised intimation with stock exchanges on May 12, 2026, notifying a change in the panel composition for its upcoming conference call with analysts and investors. The call, originally announced on May 11, 2026, remains scheduled for Friday, May 15, 2026, at 3:00 PM IST, and will cover the company's audited financial results for the quarter and financial year ended March 31, 2026. The revision was filed in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Reason for Revision

The company has disclosed that one panel member from the management team is unable to attend the conference call due to an unavoidable scheduling conflict. The remaining panel members will participate as originally planned. The change has been notified as a matter of transparency and in compliance with applicable regulatory requirements. All other details of the conference call remain unchanged.

Conference Call Schedule

The key details of the analyst and investor conference call are as follows:

Revised Panel Members

The following senior members of the Solara Active Pharma Sciences leadership team are confirmed to participate in the conference call:

• Sandeep Rao – MD & CEO
• Sarat Kumar – CFO

Dial-In Details

Investors and analysts wishing to participate in the call may use the following dial-in numbers:

Additional Information

Details of the conference call are also available on the company's official website at the investor relations section. The revised intimation was signed by Pooja Jaya Kumar, Company Secretary & Compliance Officer (Membership No: A57415), on behalf of Solara Active Pharma Sciences. Stakeholders are encouraged to refer to the company's website for any updates or additional materials related to the call.

Solara Active Pharma Sciences has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration for its Puducherry manufacturing facility. The regulatory development marks a significant milestone for the pharmaceutical company's operations at this location.

FDA Inspection Timeline and Outcome

The US FDA conducted an unannounced inspection of the Puducherry facility from February 2 to February 6, 2026. The inspection has been concluded with a Voluntary Action Indicated (VAI) status, with the agency issuing the EIR on April 24, 2026, and marking the inspection as "Closed".

Management Commentary

Commenting on the inspection outcome, Sandeep Rao, MD & CEO, stated that the company successfully completed the FDA inspection at the Puducherry facility. At the end of the inspection, four Form FDA 483 inspectional observations were issued by the investigator, which were procedural in nature. The company submitted its formal response to FDA within the stipulated timeline.

"The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy," Rao added.

Facility Specifications

The Puducherry site serves as an Ibuprofen manufacturing facility equipped with world-class infrastructure to cater to Ibuprofen and its derivatives requirements for domestic and international markets. The facility has been inspected by various regulatory authorities including US FDA, EDQM, MHRA, and HPRA.

Regulatory Significance

The VAI status represents a favorable outcome for pharmaceutical manufacturing facilities undergoing FDA inspection. This classification demonstrates that the Puducherry facility maintains appropriate manufacturing practices and quality standards as required by US regulatory authorities. The successful closure of the unannounced inspection exhibits the company's dedication to achieving quality excellence consistently across all manufacturing sites.